With many new agents designed to treat PsA, rheumatologists and patients have options. Schwartzman et al. examined the real-world use of different treatments and ranked patient medication preferences.
Search results for: Tofacitinib
2 New Clinical Practice Guidelines for JIA Released
Two new ACR Clinical Practice Guidelines provide recommendations on the pharmacologic management of JIA, focusing on treatment of oligoarthritis, temporomandibular arthritis & systemic JIA, as well as nonpharmacologic therapies, medication monitoring, immunizations & imaging.
Common Misconceptions Clarified: Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis
At the 17th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases meeting at Johns Hopkins School of Medicine, Baltimore, Atul Deodhar, MD, discussed ankylosing spondylitis and non-radiographic axial spondyloarthritis & clarified common misconceptions about these conditions.
The Ins & Outs of Patient Assistance Programs
Although effective against rheumatic disease, biologic therapies come with hefty price tags. Patient assistance programs can be a useful resource to help under- and uninsured patients get the drugs they need.
An Oral Targeted Therapy: RheumMadness 2022 Pim Kinases Scouting Report
According to research, Pim kinases contribute to the pathogenesis of rheumatoid arthritis (RA) and may have the therapeutic potential for inhibition in patients with RA.
Insights into JAK Inhibitor Use
According to a German study presented during ACR Convergence 2021, treatment persistence with JAK inhibitors is comparable to TNF inhibitors and other bDMARDs among patients with rheumatoid arthritis.
Research on SLE, pJIA & More Highlighted in 2nd ACR Convergence 2021 Plenary Session
Experts shined a spotlight on select abstracts of the latest rheumatology research, addressing such topics as racial disparities in the management of children with SLE, vitamin D or fish oil supplementation to prevent autoimmune disease & more.
Cardiovascular Risks & Insights from ACR Convergence 2021
Experts share insights into how LDL & HDL levels are affected by inflammation & the treatment of rheumatic disease, addressing how targeting these levels may improve cardiovascular outcomes for patients.
Updates on JAK Inhibitor Safety, COVID-19 Vaccination in Immunosuppressed Patients & More
ACR CONVERGENCE 2021—The ACR Convergence 2021 meeting reflected the continued advancement of science and practical research in the field of rheumatoid arthritis (RA). Among the most important topics this year in RA was the evolution of the risk-benefit profile of Janus kinase (JAK) inhibitors, for which new safety data emerged in a series of related…
Update on Extrapulmonary Sarcoidosis
Neurosarcoidosis & sarcoid dermatopathology are discussed.
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 21
- Next Page »